Clinical significance of elevated serum interferon-inducible protein-10 levels in hepatitis C virus carriers with persistently normal serum transaminase levels

Journal of Viral Hepatitis

Volumn 8, Issue 5, 2001, Pages 341-348

  Itoh, Yoshito ^a   Morita, A ^a   Nishioji, K ^a   Narumi, S ^a   Toyama, T ^a   Daimon, Y ^a   Nakamura, H ^a   Kirishima, T ^a   Okanoue, T ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Biochemical responder; Hepatitis C virus asymptomatic carrier; Interferon therapy; Interferon inducible protein 10

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 4; VIRUS RNA;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE COUNT; TREATMENT OUTCOME; VIRUS CARRIER;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CARRIER STATE; CHEMOKINES, CXC; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-10; INTERLEUKIN-4; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0035723756     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2001.00309.x     Document Type: Article

References (50)

1. The scientific challenge of hepatitis C
2. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C
3. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: A retrospective study in 1148 patients
4. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan
5. Long-term carriage of hepatitis C virus with normal aminotransferase after interferon treatment in patients with chronic hepatitis C
6. Discrepancy between biochemical and virological response to interferon-α in chronic hepatitis C
7. Persistent hepatitis C viremia predict late relapse after sustained response to interferon-α in chronic hepatitis C
8. Serial quantitation of serum core protein and viral RNA of hepatitis C virus after interferon therapy: Increase in viral loads in biochemical responders
9. Characteristics of hepatitis C virus before and after interferon treatment in patients with ongoing viremia but sustained biochemical response
10. Hepatitis C viral quasispecies in hepatitis C virus carriers with normal liver enzymes and patients with type C chronic liver disease
11. The virological and histological state of anti-hepatitis C virus-positive subjects with normal liver biochemical values
12. Interleukin-10 inhibits expression of both interferon α- and interferon γ-induced genes by suppressing tyrosine phosphorylation of STAT1
13. Tissue-specific expression of murine IP-10 mRNA following systemic treatment with interferon gamma
14. Differential expression and regulation of chemokines JE, KC, and IP-10 gene in primary cultured murine hepatocytes
15. Expression of IFN-inducible protein-10 in chronic hepatitis
16. Immunoregulatory cytokines in chronic hepatitis C virus infection: Pre- and posttreatment with interferon alpha
17. High levels of serum interleukin-10 are associated with a poor response to interferon treatment in patients with chronic hepatitis C
18. Serum levels of IL-10, IL-15 and soluble tumor necrosis factor-alpha (TNF-α) receptors in type C chronic liver disease
19. Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection
20. Interleukin-10 suppresses IP-10 gene transcription by inhibiting the production of Class I interferon
21. Monokine production by peripheral whole blood in chronic hepatitis C patients treated with interferon
22. Circulating HCV-RNA, HCV genotype, and liver histology in asymptomatic individuals reactive for anti-HCV antibody and their follow-up study
23. Classification of chronic hepatitis: Diagnosis, grading and staging
24. Antigenicities of group I and II hepatitis C virus polypeptides: Molecular basis of diagnosis
25. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C
26. Development of a quantitative PCR assay for monitoring HCV viremia levels in patients with chronic hepatitis C
27. Clinical and virological features of chronic hepatitis C carriers with normal alanine aminotransferase levels despite positive serum HCV-RNA after interferon therapy
28. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity
29. Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the southwestern United States
30. Natural history of hepatitis C virus carriers with persistently normal amino-transferase levels
31. Time course of histological changes in patients with a sustained biochemical and virological response to interferon-α therapy for chronic hepatitis C virus infection
32. 10-Year follow-up after interferon-α therapy for chronic hepatitis C
33. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels
34. Chronic hepatitis C with normal aminotransferase levels: A clinical histologic study
35. Serum levels of soluble interleukin-2 receptors and effects of interferon a for patients with chronic hepatitis C virus
36. Serum levels of soluble tumor necrosis factor receptors and effects of interferon therapy in patients with chronic hepatitis C virus infection
37. Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins
38. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver
39. Enhanced expression of interferon-regulated genes in the liver of patients with chronic hepatitis C virus infection: Detection by suppression-subtractive hybridization
40. Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA express
41. The interferon-stimulated response element and kB site mediate synergistic induction of murine IP-10 gene transcription by IFNγ and TNFα
42. p48/STAT-1α-containing complexes play a predominant role in induction of IFN-γ-inducible protein, 10 kDa (IP-10) by IFN-γ alone or in synergy with TNFα
43. Detection of type 2-like T-helper cells in hepatitis C virus infection: Implications for hepatitis C virus chronicity
44. Interferon alfa subtypes and levels of type I interferons in the liver and peripheral mononuclear cells in patients with chronic hepatitis C and controls
45. Liver infiltrating T lymphocytes express interferon γ and inducible nitric oxide synthase in chronic hepatitis C virus infection
46. Influence of HLA halotypes on the clinical courses of individuals infected with hepatitis C virus
47. Influence of MHC class II genotype on outcome of infection with hepatitis C virus
48. Tumor necrosis factor alpha promotor polymorphism at position -1238 is associated with chronic active hepatitis C infection
49. Interleukin-10 promotor polymorphism predicts initial response od chronic hepatitis C to interferon alfa
50. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis